TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06271252: A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Sponsor: OriCell Therapeutics Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 81 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06271252 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06271252 Rescue Dossier →